Indication
encorafenib in combination with binimetinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation
Medicine details
- Medicine name:
- encorafenib (Braftovi)
- SMC ID:
- SMC2145
- Pharmaceutical company
- Pierre Fabre Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Advice due date:
- 08 July 2019
- SMC meeting date:
- 04 June 2019
- Patient group submission deadline:
- 04 March 2019